



**TEXAS MEDICAID**  
**Clinical Edit Prior Authorization**  
**deutetrabenazine (AUSTEDO),**  
**tetrabenazine (XENAZINE)**

**All Plans Except Texas Children's Health Plan**

<b>STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING</b>	
Date:	Prescriber First & Last Name:
Patient First & Last Name:	Prescriber NPI:
Patient Address:	Prescriber Address:
Patient ID:	Prescriber Phone:
Patient Date of Birth:	Prescriber Fax:
<b>STEP 2: MEDICATION INFORMATION</b>	
Medication Requested (Name):	Quantity Requested:
Dose Requested:	Dosing Instructions:
Patient's Primary Diagnosis: _____ ICD 10 Code: _____	
Indicate the drug's formulary status: *(Formulary available at <a href="http://www.txvendordrug.com">www.txvendordrug.com</a> )	
<input type="checkbox"/> Non-Preferred Drug (NPD or NAP Status, Go to Step 3 - PDL PA Criteria Applies)	
<b>OR</b> <input type="checkbox"/> Preferred Drug (Go to Step 4)	
<b>OR</b> <input type="checkbox"/> N/A as this request is for a CHIP / PERINATE client (Go to Step 4)	
<b>STEP 3: PDL PRIOR AUTHORIZATION CRITERIA FOR NON-PREFERRED PRODUCT</b>	
1. Has the client failed a 30-day treatment trial with at least 1 preferred agent in the last 180 days?	
<input type="checkbox"/> Yes (Go to Step 4 Question 1) <input type="checkbox"/> No (Go to #2)	
2. Is there a documented allergy or contraindication to preferred agents in this class?	
<input type="checkbox"/> Yes (Go to Step 4 Question 1) <input type="checkbox"/> No (Go to #3)	
3. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions?	
<input type="checkbox"/> Yes (Go to Step 4 Question 1) <input type="checkbox"/> No (Deny)	



#### STEP 4: CLINICAL PRIOR AUTHORIZATION CRITERIA

1. Is the client greater than or equal to ( $\geq$ ) 18 years of age?

Yes (Go to #2)

No (Deny)

2. Does the client have a diagnosis of Huntington-induced chorea in the last 365 days?

Yes (Go to #3)

No (And the request is for deutetrabenazine, go to #5)

No (And the request is for tetrabenazine, deny)

3. Is the medication being prescribed by, or its use overseen by, a neurologist or a psychiatrist?  
[Manual Step]

Yes (Go to #4)

No (Deny)

4. Does the client have a diagnosis of severe depression or suicide attempt/ideation in the last 180 days?

Yes (Deny)

No (Go to #6)

5. Does the client have a diagnosis of tardive dyskinesia in the last 365 days?

Yes (Go to #6)

No (Deny)

6. Does the client have a diagnosis of hepatic impairment in the last 365 days?

Yes (Deny)

No (Go to #7)

7. Does the client have one (1) claim for a monoamine oxidase (MAO) inhibitor in the last 90 days?

Examples include AZILECT, linezolid (ZYVOX), MARPLAN, phenelzine (NARDIL), selegiline (EMSAM, ZELAPAR), and tranylcypromine (PARNATE).

Yes (Deny)

No (Go to #8)

8. Has the client had one (1) claim for a strong CYP2D6 inhibitor in the last 90 days?

Examples includes bupropion (APLENZIN, FORFIVO, WELLBUTRIN, ZYBAN), fluoxetine (PROZAC), olanzapine-fluoxetine (SYMBYAX), paroxetine (BRISDELLE, PAXIL, PEXEVA), quinidine, and SENSIPAR.

Yes (Go to #9)

No (Approve - 365 days)

9. Is the daily dose less than or equal ( $\leq$ ) to 50 mg (tetrabenazine [XENAZINE]) or 36 mg (deutetrabenazine [AUSTEDO])?

Yes (Approve - 365 days)

No (Deny)



**STEP 5: SIGN AND FAX TO: NAVITUS PRIOR AUTHORIZATION AT: 855-668-8553**

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

If criteria not met, submit chart documentation with form citing complex medical circumstances.  
For questions, please call Navitus Customer Care at 1-877-908-6023.